BioCentury | Aug 18, 2020

Lilly’s global deal for Innovent PD-1 could lead to U.S. approval, adds more cash for biotech’s R&D

...death 1 ligand 1TIGIT - T cell immunoreceptor with Ig and ITIM domains Paul Bonanos Tyvyt, sintilimab (IBI308) Eli...
BioCentury | Apr 29, 2020
Product Development

April 28 Quick Takes: Syndax gains on leukemia data; plus Supernus, Neurocrine, Avadel, Insilico-Astellas, Innovent-Lilly, Chimerix

...mixed-lineage leukemia protein PD-1 (PDCD1; CD279) - Programmed cell death 1 Hongjiang Li, Staff Writer Tyvyt, sintilimab (IBI308) Avadel...
BioCentury | Feb 14, 2020

On heels of reimbursement, Innovent raises $303M to ready Tyvyt rollout

...Programmed cell death 1 PCSK9 - Proprotein convertase subtilisin/kexin type 9 Hongjiang Li, Staff Writer Tyvyt, sintilimab (IBI308) Programmed...
BioCentury | Jan 13, 2020
Company News

Jan. 13 Company Quick Takes: AZ ends fish oil trial; plus Lynparza, Lilly-NextCure, Innovent, Amgen-Qiagen-Guardant, Axsome-Pfizer

...receptor; K-Ras - KRAS; PD-1 (PDCD1; CD279) - Programmed cell death 1 BioCentury Staff AMG 510 Tyvyt, sintilimab (IBI308) Alimta...
BioCentury | Aug 29, 2019
Company News

Aug. 29 Company Quick Takes: EC approves Tecentriq for breast cancer, Giapreza for hypotension; plus Innovent reports Tyvyt sales

...Informal) Tecentriq (Brand), RG7446 (Compound #), MPDL3280A (Compound #), atezolizumab (Generic), Tecentriq (Other), Anti-PDL1 (Other) Tyvyt, sintilimab (IBI308) Innovent...
BioCentury | Aug 6, 2019
Company News

Aug. 6 Company Quick Takes: Sales updates from Alnylam, Sage, Regeneron and GW; plus regulatory updates from MorphoSys and more

...REGN668 (Compound #), dupilumab (Generic), Dupixent (Informal) Epidiolex, Epidyolex, cannabidiol lumateperone (ITI-007) Onpattro, patisiran (ALN-TTR02, GENZ438027, GZ438027, SAR438027) sintilimab (IBI308) tafasitamab...
BioCentury | Jun 7, 2019
Clinical News

June 7 Clinical Quick Takes: Takeda discontinues Ninlaro for amyloidosis; plus La Jolla, Innovent and Atara

...Staff Writer ASTX727 EBV-CTL, tab-cel, tabelecleucel (ata 129, ata129) LJPC-401 Ninlaro (Brand), MLN9708 (Compound #), ixazomib (Generic), Ninlaro (Other) sintilimab (IBI308) Astex...
BioCentury | May 31, 2019
Company News

May 31 Company Quick Takes: NMPA accepts two BeiGene applications, approves Hengrui's PD-1 inhibitor; and more

...for patients ineligible for ASCT. Jonathan Block, Associate Editor Abraxane, nab-paclitaxel (ABI-007) Camrelizumab (INCSHR1210, SHR-1210) Darzalex, daratumumab (JNJ-54767414, humax-cd38) sintilimab (IBI308) tislelizumab...
BioCentury | Apr 19, 2019
Product Development

Companies poised to take Chinese checkpoints global

...Junshi sells Tuoyi toripalimab at an 83% discount, and Innovent Biologics Inc. sells Tyvyt sintilimab (IBI308...
BioCentury | Apr 5, 2019
Product Development

Pazdur on pandemonium: calls for collaboration, competition on PD-1 drugs

...Keytruda. Another Chinese company, Innovent Biologics, set the price of its anti-PD-1 mAb Tyvyt sintilimab (IBI308...
Items per page:
1 - 10 of 41